Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2
Journal Article
·
· Nature Communications
more »
- Northwestern Univ., Chicago, IL (United States)
- Univ. of Texas MD Anderson Cancer Center, Houston, TX (United States)
- Northwestern Univ. Feinberg School of Medicine, Chicago, IL (United States)
- Univ. of Chicago Howard T. Ricketts Lab. and Department of Microbiology, Chicago, IL (United States)
- Texas A & M Univ., College Station, TX (United States)
- Northwestern Univ., Chicago, IL (United States); Univ. of Texas MD Anderson Cancer Center, Houston, TX (United States); Northwestern Univ., Evanston, IL (United States)
- Univ. of Texas MD Anderson Cancer Center, Houston, TX (United States); Rice Univ., Houston, TX (United States); Baylor College of Medicine, Houston, TX (United States)
- Northwestern Univ., Chicago, IL (United States); Northwestern Univ. Feinberg School of Medicine, Chicago, IL (United States)
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the pandemic of the coronavirus induced disease 2019 (COVID-19) with evolving variants of concern. It remains urgent to identify novel approaches against broad strains of SARS-CoV-2, which infect host cells via the entry receptor angiotensin-converting enzyme 2 (ACE2). Herein, we report an increase in circulating extracellular vesicles (EVs) that express ACE2 (evACE2) in plasma of COVID-19 patients, which levels are associated with severe pathogenesis. Importantly, evACE2 isolated from human plasma or cells neutralizes SARS-CoV-2 infection by competing with cellular ACE2. Compared to vesicle-free recombinant human ACE2 (rhACE2), evACE2 shows a 135-fold higher potency in blocking the binding of the viral spike protein RBD, and a 60- to 80-fold higher efficacy in preventing infections by both pseudotyped and authentic SARS-CoV-2. Consistently, evACE2 protects the hACE2 transgenic mice from SARS-CoV-2-induced lung injury and mortality. Furthermore, evACE2 inhibits the infection of SARS-CoV-2 variants (α, β, and δ) with equal or higher potency than for the wildtype strain, supporting a broad-spectrum antiviral mechanism of evACE2 for therapeutic development to block the infection of existing and future coronaviruses that use the ACE2 receptor.
- Research Organization:
- Pacific Northwest National Laboratory (PNNL), Richland, WA (United States)
- Sponsoring Organization:
- USDOE
- Grant/Contract Number:
- AC05-76RL01830
- OSTI ID:
- 1846287
- Report Number(s):
- PNNL-SA-169658
- Journal Information:
- Nature Communications, Journal Name: Nature Communications Journal Issue: 1 Vol. 13; ISSN 2041-1723
- Publisher:
- Nature Publishing GroupCopyright Statement
- Country of Publication:
- United States
- Language:
- English
Similar Records
Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects
Distinct Conformations of SARS-CoV-2 Omicron Spike Protein and Its Interaction with ACE2 and Antibody
Journal Article
·
Mon Jun 21 20:00:00 EDT 2021
· Cell Reports
·
OSTI ID:1815023
Distinct Conformations of SARS-CoV-2 Omicron Spike Protein and Its Interaction with ACE2 and Antibody
Journal Article
·
Mon Feb 13 19:00:00 EST 2023
· International Journal of Molecular Sciences (Online)
·
OSTI ID:2471224